Top

Published in:

01-02-2019 | Original paper

Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study

Authors: Rhonda Arthur, Henrik Møller, Hans Garmo, Christel Häggström, Lars Holmberg, Pär Stattin, Håkan Malmström, Mats Lambe, Niklas Hammar, Göran Walldius, David Robinson, Ingmar Jungner, Mieke Van Hemelrijck

Published in: Cancer Causes & Control | Issue 2/2019

Abstract

Purpose

Lifestyle-related conditions such as obesity are associated with prostate cancer progression, but the associations with hyperglycemia and dyslipidemia are unclear. This study, therefore, aims to examine the association of glucose, triglycerides, and total cholesterol with prostate cancer death.

Methods

From the Swedish AMORIS cohort, we selected 14,150 men diagnosed with prostate cancer between 1996 and 2011 who had prediagnostic measurements of serum glucose, triglycerides, and total cholesterol. Multivariable Cox proportional hazards regression models were used to determine the hazard ratios for death in relation to the aforementioned metabolic markers.

Results

Using clinical cut-off points, a non-significant positive association was observed between glucose and prostate cancer death. When compared to those with glucose in the lowest quartile, those in the highest quartile had greater risk of prostate cancer death (HR 1.19; 95% CI 1.02–1.39). However, neither total cholesterol nor triglycerides were associated with prostate cancer death. Glucose and triglycerides were positively associated with overall, cardiovascular, and other deaths. Hypercholesterolemia was only associated with risk of CVD death.

Conclusion

Our results suggest that glucose levels may influence prostate cancer survival, but further studies using repeated measurements are needed to further elucidate how glucose levels may influence prostate cancer progression.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210 CrossRefPubMed

World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. 2014. Available http://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf. Accessed 11 Nov 2014

Kenfield SA, Batista JL, Jahn JL, Downer MK, Van Blarigan EL, Sesso HD et al (2016) Development and application of a lifestyle score for prevention of lethal prostate cancer. J Natl Cancer Inst 108:djv329. https://doi.org/10.1093/jnci/djv329 CrossRefPubMed

Kenfield SA, DuPre N, Richman EL, Stampfer MJ, Chan JM, Giovannucci EL (2014) Mediterranean diet and prostate cancer risk and mortality in the health professionals follow-up study. Eur Urol 65:887–894. https://doi.org/10.1016/j.eururo.2013.08.009 CrossRefPubMed

Moller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L et al (2014) Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark. Int J Cancer 136:1940–1947. https://doi.org/10.1002/ijc.29238 CrossRefPubMed

Cao Y, Ma J (2011) Body mass index, prostate cancer–specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4:486–501. https://doi.org/10.1158/1940-6207.CAPR-10-0229 CrossRef

Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R et al (2009) Blood glucose and risk of incident and fatal cancer in the Metabolic Syndrome and Cancer Project (Me-Can): analysis of six prospective cohorts. PLoS Med 6:e1000201. https://doi.org/10.1371/journal.pmed.1000201 CrossRefPubMedPubMedCentral

Häggström C, Stocks T, Nagel G, Manjer J, Bjørge T, Hallmans G et al (2014) Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology 25:823–828. https://doi.org/10.1097/EDE.0000000000000174 CrossRefPubMedPubMedCentral

Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567. https://doi.org/10.2337/dc06-0922. 15CrossRefPubMed

10.

Cai H, Xu Z, Xu T, Yu B, Zou Q (2015) Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res 31:336–343. https://doi.org/10.1002/dmrr.2582 CrossRef

11.

Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181–12188. https://doi.org/10.1074/jbc.272.18.12181 CrossRefPubMed

12.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60(4):207–221. https://doi.org/10.3322/caac.20078 CrossRefPubMed

13.

Yue S, Li J, Lee S, Lee HJ, Shao T, Song B et al (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab 19:393–406. https://doi.org/10.1016/j.cmet.2014.01.019 CrossRefPubMedPubMedCentral

14.

Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2010) Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 213:299–305. https://doi.org/10.1016/j.atherosclerosis.2010.08.049 CrossRefPubMed

15.

Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N et al (2011) Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 117:2086–2095. https://doi.org/10.1002/cncr.25758 CrossRefPubMed

16.

Regional Oncologic Centre in the Uppsala/Örebro Region, Sweden. 2014; Available http://www.cancercentrum.se/sv/uppsalaorebro/Funktioner/in-english/research/. Accessed 17 July 2015

17.

Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E (1998) Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization—International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 44:1641–1649PubMed

18.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033. https://doi.org/10.1016/S0140-6736(01)07098-2 CrossRefPubMed

19.

Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellström K, Fransson P et al (2012) Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 42:956–967. https://doi.org/10.1093/ije/dys068 CrossRefPubMed

20.

Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S (2006) The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 9(3):270–274. https://doi.org/10.1038/sj.pcan.4500889 CrossRefPubMed

21.

Jungner I, Walldius G, Holme I, Kolar W, Steiner E (1992) Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J Clin Lab Res 21:247–255. https://doi.org/10.1007/BF02591655 CrossRefPubMed

22.

American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 27:s5–s10. https://doi.org/10.2337/dc10-S062 CrossRef

23.

Expert Panel on Detection (2001) Evaluation, and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497. https://doi.org/10.1001/jama.285.19.2486 CrossRef

24.

National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 106:3143–3143CrossRef

25.

Orsini N, Greenland S (2011) A procedure to tabulate and plot results after flexible modelling of a quantitative covariate. Stata J 11:1–29CrossRef

26.

Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD (2000) Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 284:311–318CrossRefPubMed

27.

Liu J, Zeng F, Liu Z, Zhang C, Ling W, Chen Y (2013) Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 12:1–11. https://doi.org/10.1186/1476-511X-12-159 CrossRef

28.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. https://doi.org/10.2307/2670170 CrossRef

29.

Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L (2014) Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25:329–338. https://doi.org/10.1007/s10552-013-0334-6 CrossRefPubMed

30.

Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829–841. https://doi.org/10.1056/NEJMoa1008862 CrossRef

31.

Boursi B, Giantonio BJ, Lewis JD, Haynes K, Mamtani R, Yang Y (2016) Serum glucose and hemoglobin A1C 448 levels at cancer diagnosis and disease outcome. Eur J Cancer 59:90–98. https://doi.org/10.1016/j.ejca.2016.02.018 CrossRefPubMedPubMedCentral

32.

Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI (2009) Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 20:1181–1192. https://doi.org/10.1007/s10552-009-9319-x CrossRefPubMed

33.

Merrill RM, Bird JS (2002) Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 13:435–443CrossRefPubMed

34.

Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL (2015) Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 27:105–113. https://doi.org/10.1007/s10552-015-0687-0 CrossRefPubMed

35.

Sadeghi RN, Karami-Tehrani F, Salami S (2015) Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. Tumour Biol 36:2893–2905. https://doi.org/10.1007/s13277-014-2919-4 CrossRefPubMed

36.

Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al (2007) Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99:1793–1800. https://doi.org/10.1093/jnci/djm231 CrossRefPubMed

37.

Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C et al (2011) Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 22:801–807. https://doi.org/10.1093/annonc/mdq443 CrossRefPubMed

38.

Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG et al (2016) Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. Br J Urol Int. https://doi.org/10.1111/bju.13428 CrossRef

39.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284. https://doi.org/10.1016/j.bbamcr.2006.10.001 CrossRefPubMed

40.

Sekine Y, Koike H, Nakano T, Nakajima K, Takahashi S, Suzuki K (2009) Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor. Cancer Epidemiol 33:16–23. https://doi.org/10.1016/j.canep.2009.04.004 CrossRefPubMed

41.

Kim JH, Cox ME, Wasan KM (2014) Effect of simvastatin on castration-resistant prostate cancer cells. Lipids Health Dis 13:56. https://doi.org/10.1186/1476-511X-13-56 CrossRefPubMedPubMedCentral

42.

Huang H, Cui X, Chen S, Goodin S, Liu Y, He Y et al (2014) Combination of lipitor and celebrex inhibits prostate cancer VCaP Cells in vitro and in vivo. Anticancer Res 34:3357–3363PubMedPubMedCentral

43.

Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB (2014) Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. Biochim Biophys Acta 1843:1839–1850. https://doi.org/10.1016/j.bbamcr.2014.04.019 CrossRefPubMedPubMedCentral

44.

Chang S, Han J, Abdelkader TS, Kim TH, Lee JM, Song J et al (2014) High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice. Prostate 74:1266–1277. https://doi.org/10.1002/pros.22843 CrossRefPubMed

45.

Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP et al (2010) A western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol 177:3180–3191. https://doi.org/10.2353/ajpath.2010.100568 CrossRefPubMedPubMedCentral

46.

Platz EA, Clinton SK, Giovannucci E (2008) Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123(7):1693–1698. https://doi.org/10.1002/ijc.23715 CrossRefPubMedPubMedCentral

47.

Häggström C, Stattin P, Stocks T, Garmo H, Holmberg L, Van Hemelrijck M (2016) Interpretation of conventional survival analysis and competing-risk analysis: an example of hypertension and prostate 491 cancer. BJU Int 118(6):850–852. https://doi.org/10.1111/bju.13494 CrossRefPubMed

48.

Bayliss E, Reifler L, Zeng C, McQuillan D, Jennifer L. Ellis J, Steiner J (2014) Competing risks of cancer mortality and cardiovascular events in individuals with multimorbidity. JOC 4(1):29–36. https://doi.org/10.15256/joc.2014.4.41 CrossRefPubMed

49.

Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S et al (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132(:923–931. https://doi.org/10.1161/CIRCULATIONAHA.114.014796 CrossRefPubMed

50.

Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P (1982) Geographic pathology of latent prostatic carcinoma. Int J Cancer 29(6):611–616. https://doi.org/10.1002/ijc.2910290602 CrossRefPubMed

Title: Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study
Authors: Rhonda Arthur
Henrik Møller
Hans Garmo
Christel Häggström
Lars Holmberg
Pär Stattin
Håkan Malmström
Mats Lambe
Niklas Hammar
Göran Walldius
David Robinson
Ingmar Jungner
Mieke Van Hemelrijck
Publication date: 01-02-2019
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 2/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-018-1093-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Physiologic serum 1,25 dihydroxyvitamin D is inversely associated with prostatic Ki67 staining in a diverse sample of radical prostatectomy patients

Non-alcoholic fatty liver disease and colorectal cancer survival

The association between longer relative leukocyte telomere length and risk of glioma is independent of the potentially confounding factors allergy, BMI, and smoking

The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer

Trends in mammography, hormone replacement therapy, and breast cancer incidence and mortality in Canadian women

Predictors of breast cancer mortality among white and black women in large United States cities: an ecologic study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer